MMIT Reality Check on Ovarian Cancer (Dec 2020)

According to our recent payer coverage analysis for ovarian cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for ovarian cancer treatments shows that under the medical benefit, about 50% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In May 2020, the FDA expanded the label of AstraZeneca and Merck & Co., Inc.’s Lynparza (olaparib) in combination with bevacizumab for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability based on an FDA-approved test.


AIS Health Staff

Related Posts
October 15

MMIT Reality Check on Hemophilia A (Factor VIII) (Oct 2021)

Read More
October 8

MMIT Reality Check on Diffuse Large B-Cell Lymphoma (Oct 2021)

Read More
October 1

MMIT Reality Check on Multiple Sclerosis (Oct 2021)

Read More


Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today